EC Ophthalmology

A 23-year-old female with intermediate uveitis presumably secondary to multiple sclerosis presented with blurred vison and floaters in the left eye. Differential diagnosis revealed no infectious condition. Retinal phlebitis and macular edema was observed in predominantly on the left eye. SD-OCT revealed macular edema and subretinal fluid on the left eye. Cranial magnetic resonance imaging showed paraventricular demyelinating plaques. Vasoproliferative tumor (RVPT) was noticed at the inferior peripheral retina. In order to prevent tractional retinal detachment, the lesion was treated with barrier laser photocoagulation and external cryotherapy. Also intravitreal anti-VEGF (bevacizumab) injection was performed. After initial intravenous pulse methyprednisolone treatment, intravitreal dexamethasone implant (Ozurdex) was injected to supress inflammation and control macular edema for longer. At last visit, vitreous was clear, macular edema resolved and visual acuity improved in both eyes. RVPT showed partial regression and remained inactive.

Keywords: Multiple Sclerosis (MS); Bevacizumab; Ozurdex; Intermediate Uveitis

1. Paroli MP., et al. “Intermediate uveitis: comparison between childhood-onset and adult-onset disease”. European Journal of Ophthalmology - SAGE Journals 24 (2014): 94-100.
2. Brockhurst RJ. “Retinoschisis. Complication of peripheral uveitis”. Archives of Ophthalmology 99 (1981): 1998-1999.
3. Shields CL., et al. “Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases”. The Journal of the American Medical Association Ophthalmology3 (2013): 328-334.
4. Shields JA., et al. “Presumed acquired retinal hemangiomas”. Ophthalmology 90 (1983): 1292‑1
5. Baines PS., et al. “Posterior non‑vascularized proliferative extraretinopathy and peripheral nodular retinal telangiectasis”. Transactions of the Ophthalmological Societies of the United Kingdom4 (1982): 487‑491.
6. Hiscott P and Mudhar H. “Is vasoproliferative tumour (reactive retinal glioangiosis) part of the spectrum of proliferative vitreoretinopathy?” Eye 23 (2009): 1851‑185
7. Suh DW., et al. “Coats’-like response in pars planitis”. Retina1 (1999): 79-80.
8. Felder KS and Brockhurst RJ. “Neovascular fundus abnormalities in peripheral uveitis”. Archives of Ophthalmology5 (1982): 750-754.
9. Heimann H., et al. “Vasoproliferative tumors of the retina”. British Journal of Ophthalmology 84 (2000): 1162-1169.
10. Pichi F., et al. “Vasoproliferative tumors in intermediate uveitis”. Retina9 (2020): 1765-1773.
11. W Saito., et al. “Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapywithbevacizumab in vasoproliferative retinal tumors”. Retina99 (2013): 1959-1967.
12. Krivosic V., et al. “Management of idiopathic retinal vasoproliferative tumors by slit-lamp laser or endolaser photocoagulation”. American Journal of Ophthalmology1 (2014): 154-161.
13. Saito W., et al. “Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors”. Retina9 (2013): 1959-1967.
14. F Manjandavida., et al. “Cryotherapy induced release of epiretinal membrane associated with retinal vasoproliferative tumor: analysis of 16 cases”. Retina8 (2014): 1644-1650.
15. Cebeci Z., et al. “Intravitreal dexamethasone implant (Ozurdex) and photodynamic therapy for vasoproliferative retinal tumours”. The Canadian Journal of Ophthalmology4 (2014): e83-e84.